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Abstract
Background: Mycobacterium tuberculosis infection can activate the immune system, leading to characteristic
pathological changes such as inflammatory granuloma, caseous necrosis, and cavity formation.
Methods: Clinical data of 187 cases of pulmonary tuberculosis (PTB) were analyzed using statistical methods, while
serum levels of complement C4b (C4b), fibronectin (FN), and prolidase (PEPD) were detected using the ELISA
method among the control, minimal PTB, moderate PTB, and advanced PTB groups.
Results: We found significantly higher levels of serum C4b and PEPD (P = 0.018, P = 0.003), and significantly lower
levels of serum FN (P < 0.001) in PTB patients. Furthermore, the serum levels of 3 proteins were significantly
different among 3 PTB groups. FN level was significantly higher in the moderate PTB group, compared with
patients in the minimal and advanced PTB groups (P < 0.05, P < 0.01). PEPD level was significantly higher in the
moderate PTB group, compared with the minimal PTB group (P < 0.05). Analysis of clinical data showed that serum
albumin, C-reactive protein (CRP), prealbumin, and C4 were significantly higher (P < 0.05), while serum globulin was
significantly lower in patients with PTB (P < 0.001). A significant negative correlation was found between C4b and
albumin, prealbumin. On the other hand, a significant positive correlation was found between C4b and globulin,
CRP, PEPD, as well as between PEPD and CRP (P < 0.05).
Conclusions: Our study showed that C4b, FN, and PEPD are associated with tissue damage, granuloma formation,
and cavity formation, respectively, in patients with PTB. The present study provides a new experimental basis to
understand the pathogenesis and pathological changes of PTB.
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Background
China has the world’s second largest tuberculosis (TB)
epidemic with 0.9 to 1.1 million new cases and 45,000 to
49,000 death cases in 2011 [1]. The fifth national TB epi-
demiological survey data showed that China’s active TB
population is up to 4.99 million, including 0.72 million
sputum smear positive patients and 1.29 million sputum
culture positive patients [2]. We found that the number
of active TB patients was even larger due to the increase
in the total population compared to 2000, indicating that
TB is still a major infectious disease in China.
Pulmonary tuberculosis (PTB) is caused by infection
of Mycobacterium tuberculosis (MTB). It is one of the
most common infectious diseases in the world. Innate
immunity provides the first line of defense against MTB
infection. In addition, complement proteins also act as a
functional bridge between innate and adaptive immunity,
thereby participating in many complex immune re-
sponses [3]. Several previous studies have shown that de-
fects in innate immunity could lead to PTB progression
[4,5] and defensins could cause increased tissue damage
[6] while, the Toll-like receptor, CD14 is required for
MTB-cell recognition [7,8]. As a part of complement
system, the mannose-binding lectin (MBL) pathway can
cause cytolysis by identifying mannose residues on the
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surface of MTB, and complement C4b (C4b) is a prod-
uct of activated complement C4 (C4) in the early stage
of MBL pathway [9]. So, we hypothesized that the C4b
levels may be associated with MTB infection and tissue
damage. It is well known that PTB undergo many char-
acteristic changes such as granuloma formation, caseous
necrosis, and cavity formation, but the molecular mech-
anisms underlying these changes remain unclear. Cur-
rently, many proteins have been demonstrated to
participate in the pathogenesis and pathological changes
of PTB, including a large amount of extracellular matrix
proteins such as matrix metalloproteinase 9 (MMP-9)
[10], tissue inhibitor of metalloproteinases-2 (TIMP-2)
[11], and osteopontin [12]. MMP-9 has been shown to
be involved in the recruitment of macrophages and tis-
sue remodeling at the early stage of granuloma forma-
tion in PTB [10]. Fibronectin (FN) is a type of
extracellular matrix proteins, which binds to β1 integrin
on the cell surface, leading to cellular adhesion to the
extracellular matrix. Considering this, there is a big
chance that FN could be involved in granuloma forma-
tion. TB cavity is formed by liquid discharge through the
bronchial tree after the hard caseum softens [13]. Kumar
et al. [14] attributed granuloma formation, caseous ne-
crosis, and liquefaction to host proteases disorder. Prote-
ase (PEPD) is a type of proteases that hydrolyzes
peptides with proline or hydroxyproline at the carboxy
terminus. All together, we hypothesized that serum C4b
(Swiss-Prot: P20851), FN (Swiss-Prot: P02751), and
PEPD (Swiss-Prot: P12955) levels may be associated with
MTB infection, tissue damage, granuloma formation,
cavity formation and other pathological changes in PTB
patients.
In this study, we explored the serum C4b, FN, and
PEPD levels in patients with PTB and healthy controls.
We divided PTB patients according to the standard of
the modified classification of the National Tuberculosis
Association (NTA) of the USA and revealed the relation-
ship between the three proteins and pathological
changes in order to clarify the role of these proteins in
the pathogenesis of clinical TB.
Methods
Patients and control subjects
A total of 187 subjects with pulmonary tuberculosis
were recruited from the Sixth Hospital of Shaoxing. A
total of 115 subjects, aged 18–70 years (mean age 41.6 ±
17.2 years) were tested by ELISA. The control group
comprised 39 healthy subjects, aged 23–58 years (mean
age 39.9 ± 9.9 years), and unrelated blood donors with
no history of TB or other immune diseases. Females
constituted 31.3% of the PTB patients, and 38.5% of
healthy controls (Table 1). This study was approved by
the Ethics Committee of the Faculty of Medicine
(Zhejiang University, China), and informed consent was
obtained from all subjects before blood sampling. Blood
was drawn into regular bottles in the morning from each
patient before the anti-TB therapy. Similarly, fasting
blood samples were drawn from healthy controls. The
samples were stored at - 70°C for further analysis.
Patients were diagnosed according to the diagnostic
criteria for PTB of Ministry of Health of the People’s
Republic of China [15]. All patients meet one of the
following PTB diagnostic criteria: (1) positive sputum
examination (smear or culture); (2) negative sputum
examination, chest X-ray, and CT revealing evidence of
typical active TB; (3) pathological diagnosis of TB in
lung specimens; (4) suspected of having PTB after clin-
ical follow-up and X-ray observations, and excluding
other lung diseases; (5) clinically ruling out other causes
of pleural effusion, and diagnosis of tuberculous pleurisy.
All patients were classified as having minimal, moderate
or advanced PTB using a modified classification of the
NTA [16,17]. The study group comprised 115 PTB pa-
tients classified as minimal (N = 39), moderate (N = 41),
or advanced (N = 35) PTB. There was no significant dif-
ference in the age and gender distribution among the
three groups.
ELISA methods
Human C4b ELISA Kit (Cusabio Biotech Co., LTD,
China), with a detection limit of 15.6 ng/mL, was used
to detect C4b in serum. Human FN ELISA Kit (Abnova
Table 1 Characteristics of pulmonary tuberculosis patients and healthy controls
PTB patients (N = 115) Controls (N = 39) P
Age, years range (mean ± SD) 18−70 (41.6 ± 17.2) 23−58 (39.9 ± 9.9) 0.582a
Gender: female, no. (%) 36 (31.3) 15 (38.5) 0.711b
Body mass index (mean ± SD) 21.3 ± 3.2 23.2 ± 4.3 0.213a
Tuberculin skin test (>10 mm), no. (%) 66 (57.4) ND /
Positive sputum smears, no. (%) 63 (54.8) ND /
Presence of TB history of relatives, no. (%) 11 (9.6) 3 (7.7) 0.747b
BCG vaccination, no. (%) 48 (41.7) 21 (53.8) 0.426b
A P-value of less than 0.05 indicates statistical significance. PTB: pulmonary tuberculosis; N: number of subjects; ND: not determined. aP value between PTB
patients and controls, for t test. bP value between PTB patients and controls, for χ2 test.
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Co., Taipei, Taiwan), with a minimum detection limit of
0.31 ng/mL, was used to detect FN in serum. Human
PEPD ELISA kit (Cusabio Biotech. Co., LTD, China),
with a minimum detection limit of 93.75 mU/mL, was
used to detect PEPD in serum. The protein concentra-
tion of 39 healthy controls and 115 PTB patients were
measured according to the manufacturer’s instructions.
Briefly, serum samples were diluted with dilution factors
of 1:2,000, 1:1,000,000 and 1:10 for C4b, FN and PEPD,
respectively. Diluted samples were incubated in microti-
ter wells coated with antibodies of proteins. After incu-
bation and washing, the biotinylated tracer antibody
conjugated with streptavidin-peroxidase was added to
the wells. Substrate tetramethylbenzidine (TMB) was
added to the wells after a second incubation and wash-
ing, and then the oxalic acid was added to stop the
enzyme reaction. Absorbance was read on xMark micro-
plate spectrophotometer (Bio-Rad, Inc., USA) at a wave-
length of 450 nm. The concentration of the protein was
estimated using a four-parameter logistic curve (Micro-
plate Manager 6 software, Bio-Rad, Inc., USA) based on
the measured standard values.
Statistical analysis
Parametric data were presented as mean ± SD while non-
parametric data were presented as median ± IQR, and
P < 0.05 was considered as statistically significant by the
SPSS software, version 16.0 (SPSS, Chicago, IL). The One-
sample t-test was used to investigate the difference between
PTB patients and normal reference range after taking the
logarithm. Two groups’ data were tested using the chi-
square test for composition ratio and t-test for means. Non-
parametric analysis was carried out using the Mann–
Whitney U-test. Spearman correlation method was
performed to determine association between two different
parameters. The study sample provided 88.93% power to
identify significant differences between whole PTB patients
and healthy controls at a statistical support level of α = 0.05
with an d of 0.6 applying a two tails model, and provided
75.47% power when identifying significant differences be-
tween minimal, moderate, advanced PTB groups and
healthy controls.
Results
Clinical data analysis of 187 PTB cases showed various
significant differences between PTB patients and healthy
controls of different parameters (Table 2). Comparison
of 115 PTB patients and 39 healthy controls by using
the ELISA method showed significant higher levels of
serum C4b and PEPD (P = 0.018, P = 0.003), and signifi-
cant lower level of FN (P < 0.001) in PTB patients
(Figure 1).
Table 2 Clinical data of pulmonary tuberculosis patients (N = 187) and normal reference ranges
PTB patients (mean ± SD) Normal reference ranges Median Pa
Total protein (g/L) 68.32 ± 6.66 64.00 − 83.00 72.88 < 0.001**
Albumin (g/L) 37.94 ± 5.13 36.00 − 52.00 43.27 < 0.001**
Globulin (g/L) 30.27 ± 5.60 22.00 − 34.00 27.35 < 0.001**
A/G 1.29 ± 0.32 1.20 − 2.50 1.73 < 0.001**
CRP (mg/L) 29.69 ± 38.72 0.00 − 0.82 0.41 < 0.001**
Prealbumin (g/L) 0.18 ± 0.08 0.15 − 0.36 0.23 < 0.001**
Fibrinogen (g/L) 5.69 ± 2.23 1.90 − 5.60 3.26 < 0.001**
Triglyceride (mmol/L) 1.06 ± 0.67 0.56 − 1.69 1.05 0.001**
LDH (U/L) 167.55 ± 54.74 100.00 − 240.00 154.92 0.064
HDL-C (mmol/L) 1.03 ± 0.34 1.03 − 1.55 1.26 < 0.001**
LDL-C (mmol/L) 2.31 ± 0.81 0.00 − 3.10 1.55 < 0.001**
Lipoprotein (mg/L) 270.60 ± 275.90 0.00 − 300.00 150.00 0.004**
APOA1 (g/L) 1.05 ± 0.23 1.20 − 1.60 1.39 < 0.001**
APOB (g/L) 0.76 ± 0.20 0.80 − 1.05 0.92 < 0.001**
IgG (g/L) 14.05 ± 3.60 11.50 − 14.22 12.79 0.007**
IgA (g/L) 2.84 ± 1.37 1.70 − 3.25 2.35 0.044*
IgM (g/L) 1.21 ± 0.57 0.73 − 1.17 0.92 < 0.001**
Complement 4 (mg/L) 377.78 ± 80.38 100.00 − 400.00 200.00 < 0.001**
Complement 3 (g/L) 1.04 ± 0.24 0.83 − 1.77 1.21 < 0.001**
A P-value of less than 0.05 indicates statistical significance. PTB: pulmonary tuberculosis; N: number of subjects; A/G: Albumin/ Globulin; CRP: C-reactive protein;
LDH: Lactate dehydrogenase; HDL-C: High-density lipoprotein cholesterol; LDL-C: Low-density lipoprotein cholesterol; APOA1: apolipoprotein A1; APOB:
apolipoprotein B; *P < 0.05; **P < 0.01. aP value between TB patients and normal reference range, for one-sample t-test after taking the logarithm then compare to
the median.
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Then, we compared the control group with the min-
imal, moderate, and advanced PTB groups. Our results
indicated that the levels of serum C4b were different
among groups (P = 0.024). There were significant differ-
ences in serum C4b levels of the moderate and advanced
PTB groups, compared to the control group (P < 0.05,
P < 0.01) (Figure 2A). We also found different levels of
FN (P < 0.001) among groups. FN level was found to be
significantly different in the moderate PTB group, com-
pared with patients in the minimal and advanced PTB
groups (P < 0.05, P < 0.01), not to mention the control
and minimal (P < 0.01), and the control and advanced
PTB groups (P < 0.01) (Figure 2B). PEPD also showed
different expression levels among the groups (P = 0.011).
There were significant differences in serum PEPD levels
between all three PTB groups and the control group
(P < 0.05, P < 0.01, P < 0.05). In addition, a significant
higher PEPD level was found in the moderate
PTB group than the minimal PTB group (P < 0.05)
(Figure 2C).
By using the Spearman correlation analysis, we found
a significant negative correlation between C4b and albu-
min, prealbumin. A significant positive correlation was
observed between C4b and globulin, CRP, PEPD, as well
as PEPD and CRP (P < 0.05) (Figure 3). After that, we
separated all 115 subjects based on age, gender, current
smoker, single/double lung lesion, cavity/non-cavity,
sputum smear results (−/+/++/+++/++++). Significant
difference of C4b level was found between smokers and
non-smokers (P = 0.012), as well as PEPD level between
males and females (P = 0.011) (Table 3). In addition, FN
was related to sputum smear positive results (rs = 0.22,
P = 0.028) (Table 4).
Discussion
Innate immunity is the body’s first line of defense against
MTB infection. As a part of the complement system, the
MBL pathway can cause cytolysis by identifying mannose
residues on the surface of MTB. C4b is a product of acti-
vated C4 in the early stage of MBL pathway [9]. Clinical
data analysis showed liver dysfunction (decreased albumin),
immune system activation (increased globulin), and com-
plement system activation (increased C4, C3) in PTB pa-
tients (Table 2). Similar findings were observed by ELISA
method (Figure 1A). Correlation analysis demonstrated a
weak but significant correlation between C4b and albumin,
globulin (P < 0.05) (Figure 3A, 3B), indicating that the re-
duction of liver synthetic function, and the activation of
Figure 1 Serum C4b, FN, and PEPD levels between controls and pulmonary tuberculosis patients. A P-value of less than 0.05 indicates
statistical significance using the Mann–Whitney U-test. PTB: pulmonary tuberculosis; *P < 0.05; **P < 0.01. A: the levels of C4b; B: the levels of FN;
C: the levels of PEPD.
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immune and complement systems occurred in the early
stage of PTB. Kingery et al. [18] revealed that increased
plasma C4b may enhance the tissue damage by inflamma-
tory response, indicating C4b as a prognostic biomarker of
type I diabetes. In our study, a significant difference in C4b
expression was observed in the moderate and advanced
PTB patients, compared to the control group (P < 0.05),
suggesting that a larger amount of bacterial infection may
cause complement system activation, tissue damage, and
cavity formation, which is also proven by Yoon et al. [19].
PTB is characterized by necrotizing granulomatous in-
flammation of the lung tissue. FN is an extracellular glyco-
protein that binds to β1 integrin on the cell surface, leading
to cellular adhesion to the extracellular matrix. There are
two types of FN: plasma fibronectin (pFN), a soluble dimer
present in the body fluid, and cellular fibronectin (cFN), an
insoluble oligomer present in the extracellular matrix [20].
Fibroblasts could secrete proteases, such as metalloprotein-
ase to digest pFN at first, and then secrete cFN to form
extracellular matrix during the tissue injury. This may be
the reason for the decreased serum FN levels (P < 0.001) in
PTB patients in our study. Moreover, Kim et al. [21] re-
vealed increased serum pFN in retinoic acid-deficient mice,
which could be reversed by adding exogenous retinoic acid.
Retinol-binding protein 4 (RBP4) is responsible for binding
and transporting blood retinol into the cells to become ret-
inoic acid, and RBP4 reduction was observed previously in
PTB patients [22]. Therefore, we hypothesized that reduced
RBP4 protein may be related to the FN reduction in PTB
patients. RBP4 transport retinol into the cell, resulting
in increased intracellular retinoic acid and decreased
serum FN.
Interestingly, there was a higher level of FN in the
moderate PTB group, compared to both minimal and
advanced PTB groups (P < 0.05, P < 0.01). FN is thought
to be the earliest biomarker of Schistosoma haemato-
bium and Schistosoma mansoni infested granuloma [23].
Rojas et al. [24] demonstrated that phosphatidylinositol
mannoside of MTB can bind to α5β1 integrin on CD4+
T cells, resulting in T cell adhesion to FN in granuloma.
So, we suggested that a higher FN level in moderate
PTB patients is related to the granuloma formation. In
addition, correlation between FN and sputum smear
positive results (rs = 0.22, P = 0.028) supported our sug-
gestion. As the disease progresses, advanced PTB
patients had a reduced level of serum FN, which may be
caused by the increased expression of proteases, result-
ing in increased FN digestion.
Figure 2 Serum C4b, FN, PEPD levels between controls and pulmonary tuberculosis patients classified by NTA classification. A P-value
of less than 0.05 indicates statistical significance using the Mann–Whitney U-test. Min-PTB: minimal PTB; Mod-PTB: moderate PTB; Adv-PTB:
advanced PTB; *P < 0.05; **P < 0.01. A: the levels of C4b; B: the levels of FN; C: the levels of PEPD.
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Host proteases disorders can cause granuloma for-
mation, caseous necrosis, and liquefaction, leading to
collagen degradation and tissue damage. PEPD is a
type of proteases that hydrolyzes peptides with
proline or hydroxyproline at the carboxy terminus.
Myara et al. [25] demonstrated a higher plasma
PEPD activity in the early stage of chronic liver dis-
ease, indicating its role in the extracellular matrix
Figure 3 Correlations between serum C4b, PEPD and some biochemical parameters. A P-value of less than 0.05 indicates statistical
significance using the Spearman correlation method. The range of rs from −0.3 to −0.1 or from 0.1 to 0.3 means weak correlation, while the
range from −0.5 to −0.3 or from 0.3 to 0.5 means moderate correlation. A: correlation of C4b and albumin; B: correlation of C4b and globulin;
C: correlation of C4b and C-reactive protein; D: correlation of C4b and prealbumin; E: correlation of C4b and PEPD; F: correlation of PEPD and
C-reactive protein.
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Table 3 Average serum levels of proteins according to the clinical characteristics of the pulmonary tuberculosis
patients
Clinical characteristics (Cases) C4b (μg/mL) Pa FN (μg/mL) Pa PEPD (mU/mL) Pa
Age 0.651 0.139 0.499
18−34 (51) 663.83 ± 482.42 1,931.50 ± 3,389.50 784.47 ± 492.87
35−49 (19) 610.22 ± 539.22 837.00 ± 1,338.00 764.53 ± 724.93
≥50 (45) 772.48 ± 508.49 1,567.00 ± 2,292.00 931.92 ± 647.87
Gender 0.698 0.545 0.011*
Male (79) 694.83 ± 525.59 1,637.50 ± 3,085.25 878.56 ± 628.99
Female (36) 747.14 ± 417.058 1,274.00 ± 2,198.00 672.24 ± 341.35
Current smoker 0.012* 0.838 0.205
Yes (50) 614.25 ± 464.86 1,582.50 ± 3,446.25 925.33 ± 635.58
No (65) 818.59 ± 471.98 1,511.00 ± 2,285.50 778.75 ± 557.74
Lung lesion 0.320 0.692 0.357
Single (53) 645.45 ± 444.61 1,550.00 ± 1,705.00 778.75 ± 380.34
Double (62) 808.42 ± 454.55 1,582.50 ± 3,508.75 845.27 ± 856.62
Chest X-ray 0.555 0.739 0.878
Non-cavity (70) 663.83 ± 664.71 1,567.00 ± 1,675.00 833.59 ± 405.02
Cavity (45) 729.10 ± 389.30 1,637.50 ± 3,566.75 755.98 ± 871.74
Sputum smear 0.258 0.121 0.441
Negative (52) 645.45 ± 526.00 1,509.00 ± 1,925.75 771.10 ± 326.47
1+ (13) 587.64 ± 326.10 1,189.00 ± 1,348.00 1,079.22 ± 810.94
2+ (18) 976.66 ± 500.99 1,725.00 ± 2,333.00 819.06 ± 674.19
3+/4+ (32) 791.67 ± 409.65 2,504.00 ± 3,974.50 925.33 ± 833.83
NTA classification 0.024* < 0.001** 0.011*
Minimal PTB (39) 567.63 ± 518.38 1,528.00 ± 1,605.00 795.95 ± 258.84
Moderate PTB (41) 729.10 ± 472.71 2,894.00 ± 4,915.00 968.67 ± 759.27
Advanced PTB (35) 846.87 ± 402.95 856.00 ± 1,609.00 761.75 ± 1,895.57
All the data were presented as median ± IQR. A P-value of less than 0.05 indicates statistical significance. aP value among groups, for Mann–Whitney U-test.
*P < 0.05; **P < 0.01.
Table 4 Correlations for clinical characteristics and serum protein levels of the pulmonary tuberculosis patients
(N = 115)
Sputum smear NTA classification C4b FN PEPD
Sputum smear rs 1 0.19 0.11 0.22 0.10
Pa . 0.043* 0.244 0.028* 0.287
NTA classification rs 1 0.19 −0.18 0.08
Pa . 0.045* 0.086 0.420
C4b rs 1 0.10 0.29
Pa . 0.354 0.003**




The rs in [−0.3, -0.1] or [0.1, 0.3] means weak correlation, in [−0.5, -0.3] or [0.3, 0.5] means moderate correlation, and in [−0.7, -0.5] or [0.5, 0.7] means significant
correlation. A P-value of less than 0.05 indicates statistical significance. N: number of subjects; aP value for Spearman Correlation. *P < 0.05; **P < 0.01.
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formation. Gumus et al. [26] found a higher serum
PEPD activity in patients with PTB, especially in pa-
tients with the lung cavity. It was suggested that in-
creased PEPD level might be related to tissue
damage, enhanced fibroblast activity, and increased
levels of immunoglobulin and complement C1q
(C1q). However, our previous unpublished results,
using iTRAQ 2D LC-MS/MS technique, showed no
significant difference in serum C1q level between
PTB patients and the control group. Clinical data
analysis showed a higher levels of IgG, IgA, and IgM
in patients with PTB (P < 0.05) (Table 2), supporting
the speculation that high immunoglobulin levels can
lead to increased PEPD level. Therefore, we hypothe-
sized that increased serum PEPD level might be re-
lated to tissue damage, enhanced fibroblastic activity,
and increased immunoglobulin. Significantly higher
levels of PEPD in moderate PTB patients, compared
to minimal PTB patients (P < 0.05) indicated that
PEPD may be involved in the granuloma substrate
hydrolysis process leading to the cavity formation.
Furthermore, there was a significant difference in
C4b level between smokers and non-smokers
(P = 0.012), and a significant difference was observed
in PEPD level between males and females (P = 0.011).
We suggested that the lower level of C4b in current
smokers may be caused by a reactive inhibition in-
duced by the activation of complement system than
non-smokers before MTB infection. The reason for
higher level of PEPD in males may be due to the
higher ratio of hepatitis B infection among males
leading to liver fibrosis [27], as PEPD is an early in-
dicator of liver fibrosis [25].
Conclusion
In conclusion, we revealed increased serum C4b and
PEPD levels, and decreased FN level in PTB patients.
C4b may be associated with tissue damage, while FN
and PEPD are associated with granuloma and cavity
formation, respectively. The study provides a new
experimental basis to understand the pathogenesis
and pathological changes of PTB.
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